BR112014004587A2 - combinações sinérgicas de inibidores de pi3k- e de mek - Google Patents

combinações sinérgicas de inibidores de pi3k- e de mek

Info

Publication number
BR112014004587A2
BR112014004587A2 BR112014004587A BR112014004587A BR112014004587A2 BR 112014004587 A2 BR112014004587 A2 BR 112014004587A2 BR 112014004587 A BR112014004587 A BR 112014004587A BR 112014004587 A BR112014004587 A BR 112014004587A BR 112014004587 A2 BR112014004587 A2 BR 112014004587A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
pi3k
mek
synergistic combinations
amide
Prior art date
Application number
BR112014004587A
Other languages
English (en)
Portuguese (pt)
Inventor
Fritsch Christine
Di Tomaso Emmanuelle
Gce Cosaert Jan
Boehm Markus
Huang Xizhong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014004587A2 publication Critical patent/BR112014004587A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014004587A 2011-08-31 2012-08-30 combinações sinérgicas de inibidores de pi3k- e de mek BR112014004587A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529380P 2011-08-31 2011-08-31
US201161542463P 2011-10-03 2011-10-03
PCT/US2012/052955 WO2013066483A1 (en) 2011-08-31 2012-08-30 Synergistic combinations of pi3k- and mek-inhibitors

Publications (1)

Publication Number Publication Date
BR112014004587A2 true BR112014004587A2 (pt) 2017-03-14

Family

ID=47720713

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004587A BR112014004587A2 (pt) 2011-08-31 2012-08-30 combinações sinérgicas de inibidores de pi3k- e de mek

Country Status (11)

Country Link
US (1) US9675595B2 (enExample)
EP (1) EP2750675A1 (enExample)
JP (1) JP6058009B2 (enExample)
KR (1) KR20140072028A (enExample)
CN (1) CN103764144B (enExample)
AU (1) AU2012333092B2 (enExample)
BR (1) BR112014004587A2 (enExample)
CA (1) CA2846454A1 (enExample)
MX (1) MX2014002471A (enExample)
RU (1) RU2607944C2 (enExample)
WO (1) WO2013066483A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
PE20180318A1 (es) 2011-01-10 2018-02-09 Infinity Pharmaceuticals Inc Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
EP3007693A1 (en) * 2013-06-11 2016-04-20 Novartis AG Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
US20160129003A1 (en) * 2013-06-18 2016-05-12 Novartis Ag Pharmaceutical Combinations
BR112016012141A2 (pt) * 2014-01-15 2017-08-08 Novartis Ag "combinações farmacêuticas, uso das mesmas, e embalagem comercial"
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2017079399A1 (en) * 2015-11-03 2017-05-11 Genentech, Inc. Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
EP3849545A1 (en) * 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of neurofibromatosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
RU2192861C1 (ru) 2001-06-29 2002-11-20 Новосибирский институт биоорганической химии СО РАН Композиция для антибластической терапии
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TWI338685B (en) * 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MXPA06014478A (es) 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
US20090105250A1 (en) * 2005-01-26 2009-04-23 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20080019236A (ko) 2005-05-18 2008-03-03 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2009002927A (es) 2006-09-15 2009-03-31 Pfizer Prod Inc Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
MX336723B (es) 2008-07-11 2016-01-28 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
ES2609767T3 (es) * 2009-10-12 2017-04-24 F. Hoffmann-La Roche Ag Combinaciones de un inhibidor de PI3K y un inhibidor de MEK

Also Published As

Publication number Publication date
AU2012333092B2 (en) 2016-04-21
EP2750675A1 (en) 2014-07-09
CN103764144B (zh) 2016-07-20
AU2012333092A1 (en) 2014-03-06
WO2013066483A1 (en) 2013-05-10
RU2014112198A (ru) 2015-10-10
CN103764144A (zh) 2014-04-30
JP6058009B2 (ja) 2017-01-11
RU2607944C2 (ru) 2017-01-11
KR20140072028A (ko) 2014-06-12
MX2014002471A (es) 2014-03-27
CA2846454A1 (en) 2013-05-10
US9675595B2 (en) 2017-06-13
US20140179744A1 (en) 2014-06-26
JP2014525454A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
BR112014004587A2 (pt) combinações sinérgicas de inibidores de pi3k- e de mek
BR112015030578A2 (pt) combinações farmacêuticas
BR112015001212A2 (pt) terapia de combinação de inibidores de igf1 r e pi3k
BR112022008020A2 (pt) Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
IN2015DN00376A (enExample)
BR112016012506A8 (pt) combinações farmacêuticas, seus usos, e uso de um portador de dados
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
JP2014525454A5 (enExample)
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
BR112014008036A2 (pt) tratamento de rinite
BR112014030099A2 (pt) combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
IN2015DN00528A (enExample)
BR112014023423A2 (pt) terapia de combinação
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
BR112015012497A2 (pt) combinações farmacêuticas
BR112013018598A2 (pt) composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.